Down-regulation of heparanase leads to the inhibition of invasion and proliferation of A549 cells in vitro and in vivo

被引:6
作者
Chen, Zhitao [1 ]
Zhu, Liangming [1 ]
Li, Xiaohua [1 ]
Tian, Hui [2 ]
Fang, Yusong [1 ]
Liu, Haibo [1 ]
Li, Shuhai [2 ]
Li, Lin [2 ]
Yue, Weiming [2 ]
Li, Wenjun [2 ]
机构
[1] Shandong Univ, Jinan Cent Hosp, Dept Thorac Surg, Jinan 250013, Peoples R China
[2] Shandong Univ, Qilu Hosp, Dept Thorac Surg, Jinan 250012, Peoples R China
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; heparanase; antisense oligodeoxynucleotide; invasion; proliferation; ANTISENSE-MEDIATED SUPPRESSION; SULFATE PROTEOGLYCANS; CANCER METASTASIS; ANGIOGENESIS; HEPARIN;
D O I
10.1093/abbs/gms109
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heparanase is a mammalian endoglycosidase that degrades heparan sulfate at the cell surface and in the extracellular matrix. The expression of heparanase was detected in a wide variety of human malignant tumors and closely associated with tumor invasion, metastasis, and angiogenesis. However, the specific roles of heparanase and its mechanisms of regulating the malignant potential of non-small cell lung cancer (NSCLC) cells still remain unclear. In the present study, the expression of heparanase was down-regulated in NSCLC cell line by antisense oligodeoxynucleotide. Results showed that down-regulation of heparanase led to significant inhibition of invasive and proliferative potentials of A549 cells in vitro and in vivo. Further research demonstrated that downregulation of heparanase significantly inhibited the angiogenic potential of A549 cells, which might be the mechanism responsible for the inhibition of A549 cell proliferation in BALB/c nude mice in vivo. These findings demonstrate that heparanase plays essential roles in regulating the invasion, proliferation, and angiogenesis of A549 cells.
引用
收藏
页码:188 / 193
页数:6
相关论文
共 22 条
[1]   Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis [J].
Borsig, L ;
Wong, R ;
Feramisco, J ;
Nadeau, DR ;
Varki, NM ;
Varki, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3352-3357
[2]   Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis [J].
Edovitsky, E ;
Elkin, M ;
Zcharia, E ;
Peretz, T ;
Vlodavsky, I .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (16) :1219-1230
[3]   Heparanase as mediator of angiogenesis: mode of action [J].
Elkin, M ;
Ilan, N ;
Ishai-Michaeli, R ;
Friedmann, Y ;
Papo, O ;
Pecker, I ;
Vlodavsky, I .
FASEB JOURNAL, 2001, 15 (07) :1661-+
[4]   Cancer metastasis:: Building a framework [J].
Gupta, Gaorav P. ;
Massague, Joan .
CELL, 2006, 127 (04) :679-695
[5]   Heparan sulphate proteoglycans:: The sweet side of development [J].
Häcker, U ;
Nybakken, K ;
Perrimon, N .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2005, 6 (07) :530-541
[6]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[7]   Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis [J].
Ilan, Neta ;
Elkin, Michael ;
Vlodavsky, Israel .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (12) :2018-2039
[8]   Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world [J].
Kamangar, Farin ;
Dores, Graca M. ;
Anderson, William F. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (14) :2137-2150
[9]  
Khuri FR, 2000, CLIN CANCER RES, V6, P1607
[10]   A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma [J].
Lewis, Karl D. ;
Robinson, William A. ;
Millward, Michael J. ;
Powell, Alex ;
Price, Timothy J. ;
Thomson, Damien B. ;
Walpole, Euan T. ;
Haydon, Andrew M. ;
Creese, Brian R. ;
Roberts, Kaye L. ;
Zalcberg, John R. ;
Gonzalez, Rene .
INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) :89-94